News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
147,452 Results
Type
Article (11314)
Company Profile (53)
Press Release (136085)
Multimedia
Podcasts (7)
Webinars (3)
Section
Business (41012)
Career Advice (115)
Deals (7245)
Drug Delivery (10)
Drug Development (19446)
Employer Resources (14)
FDA (3409)
Job Trends (2818)
News (71174)
Policy (6433)
Tag
2027 Genetown Elite (1)
2027 Genetown Standard (1)
Academia (723)
Accelerated approval (10)
Adcomms (5)
Allergies (22)
Alliances (14235)
ALS (48)
Alzheimer's disease (442)
Antibody-drug conjugate (ADC) (78)
Approvals (3551)
Artificial intelligence (95)
Autoimmune disease (24)
Automation (6)
Bankruptcy (23)
Best Places to Work (2503)
BIOSECURE Act (3)
Biosimilars (68)
Biotechnology (49)
Bladder cancer (41)
Brain cancer (24)
Breast cancer (113)
Cancer (1100)
Cardiovascular disease (101)
Career advice (101)
Career pathing (2)
CAR-T (70)
Celiac Disease (1)
Cell therapy (219)
Cervical cancer (3)
Clinical research (16455)
Collaboration (542)
Compensation (194)
Complete response letters (18)
COVID-19 (550)
CRISPR (55)
C-suite (188)
Cystic fibrosis (93)
Data (1696)
Denatured (1)
Depression (19)
Diabetes (81)
Diagnostics (2064)
Digital health (6)
Diversity (1)
Diversity, equity & inclusion (7)
Drug discovery (77)
Drug pricing (5)
Duchenne muscular dystrophy (124)
Earnings (14319)
Editorial (8)
Employer branding (3)
Employer resources (13)
Events (19186)
Executive appointments (172)
FDA (4241)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (7)
Frontotemporal dementia (11)
Funding (316)
Gene editing (135)
Generative AI (5)
Gene therapy (337)
GLP-1 (149)
Government (690)
Grass and pollen (1)
Guidances (88)
Healthcare (3223)
HIV (11)
Huntington's disease (23)
IgA nephropathy (32)
Immunology and inflammation (26)
Immuno-oncology (7)
Indications (25)
Infectious disease (589)
Inflammatory bowel disease (53)
Inflation Reduction Act (2)
Influenza (17)
Intellectual property (53)
Interviews (14)
IPO (3042)
IRA (1)
Job creations (491)
Job search strategy (97)
JPM (9)
Kidney cancer (1)
Labor market (3)
Layoffs (65)
Legal (1309)
Liver cancer (27)
Longevity (2)
Lung cancer (154)
Lymphoma (119)
Machine learning (6)
Management (1)
Manufacturing (176)
MASH (18)
Medical device (1421)
Medtech (1428)
Mergers & acquisitions (4479)
Metabolic disorders (212)
Multiple sclerosis (27)
NASH (2)
Neurodegenerative disease (89)
Neuropsychiatric disorders (10)
Neuroscience (769)
NextGen: Class of 2026 (921)
Non-profit (727)
Now hiring (5)
Obesity (101)
Opinion (50)
Ovarian cancer (29)
Pain (23)
Pancreatic cancer (41)
Parkinson's disease (93)
Partnered (5)
Patents (94)
Patient recruitment (105)
Peanut (1)
People (11790)
Pharmaceutical (5)
Pharmacy benefit managers (4)
Phase 1 (5513)
Phase 2 (7289)
Phase 3 (5676)
Pipeline (1324)
Policy (20)
Postmarket research (438)
Preclinical (2287)
Press Release (20)
Prostate cancer (45)
Psychedelics (3)
Radiopharmaceuticals (37)
Rare diseases (464)
Real estate (1046)
Recruiting (3)
Regulatory (5566)
Reports (12)
Research institute (863)
Resumes & cover letters (11)
Rett syndrome (26)
RNA editing (12)
RSV (5)
Schizophrenia (27)
Series A (55)
Series B (51)
Service/supplier (2)
Sickle cell disease (47)
Special edition (3)
Spinal muscular atrophy (141)
Sponsored (7)
Startups (975)
Stomach cancer (1)
Supply chain (17)
Tariffs (2)
The Weekly (6)
Vaccines (127)
Venture capital (15)
Weight loss (33)
Women's health (13)
Date
Last 7 days (133)
Last 30 days (510)
Last 365 days (6925)
2026 (707)
2025 (6964)
2024 (8276)
2023 (9196)
2022 (13869)
2021 (13765)
2020 (11951)
2019 (8845)
2018 (6729)
2017 (7373)
2016 (6641)
2015 (8023)
2014 (5865)
2013 (4846)
2012 (4799)
2011 (4901)
2010 (4437)
Location
Africa (176)
Alabama (7)
Alaska (2)
Arizona (27)
Arkansas (1)
Asia (24570)
Australia (3041)
California (2299)
Canada (674)
China (435)
Colorado (72)
Connecticut (74)
Delaware (28)
Europe (22568)
Florida (225)
Georgia (29)
Hawaii (1)
Idaho (4)
Illinois (85)
India (36)
Indiana (169)
Iowa (3)
Japan (279)
Kansas (11)
Kentucky (4)
Louisiana (7)
Maine (7)
Maryland (276)
Massachusetts (2188)
Michigan (77)
Minnesota (51)
Missouri (7)
Montana (2)
Nebraska (6)
Nevada (20)
New Hampshire (4)
New Jersey (630)
New Mexico (4)
New York (661)
North Carolina (312)
North Dakota (5)
Northern California (1168)
Ohio (55)
Oklahoma (1)
Oregon (5)
Pennsylvania (431)
Puerto Rico (2)
Rhode Island (8)
South America (220)
South Carolina (3)
Southern California (867)
Tennessee (6)
Texas (293)
United States (8296)
Utah (151)
Virginia (86)
Washington D.C. (13)
Washington State (206)
Wisconsin (19)
147,452 Results for "touchlight genetics ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Curia expands biologics capabilities with access to Touchlight’s doggybone DNACuria collaborates with Touchlight to expand its mRNA manufacturing offering to enable access to enzymatic doggybone DNA (dbDNA™)
Curia, a leading contract research, development and manufacturing organization, and Touchlight, a company pioneering enzymatic DNA production, today announced an agreement which will provide Curia and its clients a streamlined means of access to Touchlight’s doggybone DNA (dbDNA).
July 24, 2023
·
2 min read
Touchlight’s enzymatic doggybone DNA used in the manufacture of Versameb’s VMB-100 for first-in-human clinical study
Touchlight announced that the Company has used its proprietary dbDNA as a critical starting material for manufacturing of VMB-100, a potency enhanced messenger ribonucleic acid encoding human insulin-like growth factor-1 to support Versameb’s first-in-human clinical study to treat chronic stress urinary incontinence.
November 21, 2023
·
4 min read
Press Releases
Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Bid Price Deficiency
January 19, 2026
·
4 min read
Press Releases
QureBio Ltd. to Present at ASCO 2026 its Q-1802 Phase II Clinical Results
January 29, 2026
·
3 min read
Press Releases
Faron Pharmaceuticals Ltd: Appointment of CFO
December 1, 2025
·
3 min read
Press Releases
vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737
February 2, 2026
·
7 min read
FDA Accepts Drug Master File, Signifying a New Milestone for Touchlight’s Enzymatic doggybone DNA Technology
Touchlight, a biotechnology company pioneering enzymatic DNA production to enable genetic medicines, today announced a ground-breaking new milestone for its enzymatic doggybone DNA (dbDNA™), following the FDA acceptance of the Drug Master File (DMF) for GMP grade dbDNA.
January 24, 2023
·
3 min read
Press Releases
Ayrmid Pharma Ltd Announces Additional Positive Results for Omisirge(R) in Treating Severe Aplastic Anemia (SAA) Presented at TANDEM
February 5, 2026
·
4 min read
Press Releases
Faron Pharmaceuticals Ltd: Holding(s) in Company
December 5, 2025
·
3 min read
FDA
Touchlight Announces First FDA Clearance of an IND Utilising Doggybone DNA
Touchlight, a CDMO pioneering enzymatic DNA production to enable genetic medicines, today announced the first FDA clearance of an Investigational New Drug (IND) application in the US utilising doggybone DNA (dbDNA™).
February 28, 2023
·
2 min read
1 of 14,746
Next
